Skip to main content
Premium Trial:

Request an Annual Quote

BioRad to Buy DiaMed for $390M

NEW YORK (GenomeWeb News) - Bio-Rad said today it plans to buy reagent and screening tool-maker DiaMed Holding for around 477 million Swiss francs ($390 million).
 
The companies signed a definitive agreement under which Bio-Rad would buy 77.7 percent of DiaMed’s outstanding shares, after which Bio-Rad plans to conduct a tender offer buy nearly 13 percent of the remaining outstanding shares. The remaining 9.6 percent of DiaMed’s shares are treasury shares.
 
Bio-Rad said DiaMed generates roughly $200 million in annual sales to hospitals, labs, and blood banks.
 
John Goetz, Bio-Rad’s vice president and group manager of clinical diagnostics, said in a statement that DiaMed’s portfolio of products is a good fit with Bio-Rad’s existing diagnostics business.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.